1Kupperman H.Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrhea indices.J clinical Endocrinol,1953,13:688～701.
2Verheul HA,Coelingh-Bennink HJ,Kenemans P,et al.Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies.Maturitas,2000,36(1):1～17.
3Lundstrom E,Christow A,Kersemaekers W,et al.Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density.Am J Obstet Gynecol,2002,186(4):717～722.
4William D Dupont,David L Page,Fritz F Parl,et al.Estrogen replacement therapy in women with a history of proliferative breast disease.Cancer,1999,85(6):1277～1283.
6R M E Vos,S F M Krebbers,C H J Verhoeven,et al.The in vivo human metabolism of tibolone.Drug Metabolism Dispose.2002,30(2):106～112.
7P Conner,A Cbristow,W Kersemaekers,et al.A comparative study of breast cell proliferation during hormone replacement therapy:effects of tibolone and continuous combined estrogen-progestogen treament.Climacteric,2004,7:50～58.
8M B Cetinkaya,T Alper,A Kokcu,et al.Tibolone versus four estrogen replacement therapy protocols and plasma lipid levels in postmenopausal women.Inter J Obstet Gynecol,2002,79:17～23.
